M Ruthardt Selected Research

PF-114

5/2015

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Ruthardt Research Topics

Disease

3	Leukemia 05/2015 - 07/2000
3	Acute Promyelocytic Leukemia 07/2004 - 07/2000
2	Philadelphia Chromosome 05/2015 - 07/2000
2	Neoplasms (Cancer) 06/2009 - 07/2000
1	Carcinogenesis 06/2009
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/2004
1	Prolymphocytic Leukemia 01/2001
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2001
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2001
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2000
1	Myeloproliferative Disorders (Myeloproliferative Disorder) 07/2000

Drug/Important Bio-Agent (IBA)

3	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 07/2004 - 07/2000
2	ArsenicIBA 07/2004 - 07/2000
1	PF-114IBA 05/2015
1	ponatinibIBA 05/2015
1	Tyrosine Kinase InhibitorsIBA 05/2015
1	A-Form DNA (A-DNA)IBA 06/2009
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 07/2004
1	Biological ProductsIBA 07/2004
1	Messenger RNA (mRNA)IBA 01/2001
1	N 30IBA 01/2001
1	Arsenic Trioxide (Trisenox)FDA Link 07/2000
1	Phosphotransferases (Kinase)IBA 07/2000